IQVIA Pharma Deals Half-Year Review of 2024

By Lucy Haggerty, Taskin Ahmed, Ayush Saxena & Swati Sharan

Pharma Deals Review: Vol 2024 Issue 9 (Table of Contents)

Published: 17 Sep-2024

DOI: 10.3833/pdr.v2024.i9.2900     ISSN: 1756-7874

Section: Opinion & Analysis

Fulltext:

Abstract

The slowdown in deal activity in the life sciences sector that was seen in 2023 continued in H1 2024 as persistent macroeconomic headwinds discouraged dealmakers from signing certain transactions that could be perceived as ‘risky’...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details